Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cafusertib + LD-Ara-C in R/R AML
NCT02140606Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-10342 in acute myeloid leukemia (AML), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Status: unknown.
02
Drugs
HS-10342
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02140606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140606.